London, UK – [Insert Date] – Vera Therapeutics is on the cusp of securing full FDA approval for its groundbreaking IgA nephropathy (IgAN) treatment, Trutakna (atacicept-vymj), following the release of compelling confirmatory data from its pivotal Phase III ORIGIN 3 trial. The drug, which received accelerated approval in July 2026 for reducing proteinuria in specific IgAN patients, has now demonstrated significant and sustained improvements in kidney function and disease progression, bolstering its potential to become a cornerstone therapy for this chronic and debilitating kidney disease.
The latest data, presented from the ORIGIN 3 trial (NCT04716231), showcases Trutakna’s ability to not only slow but potentially halt the progression of IgAN. At 52 weeks, patients treated with Trutakna experienced a significantly smaller decline in mean estimated glomerular filtration rate (eGFR) – a key indicator of kidney function – with a reduction of just 0.1 mL/min/1.73m², compared to a substantial 5.7 mL/min/1.73m² reduction in the placebo group. This stark contrast underscores Trutakna’s potent renoprotective effects.
Looking at the longer-term trajectory, the annualised eGFR slope through 104 weeks further cemented Trutakna’s efficacy, revealing a mere 0.6 drop in the treatment arm versus a 5.6 drop in the placebo cohort. This sustained stabilization of kidney function over a two-year period is a critical finding for patients facing a disease characterized by relentless decline.
Beyond eGFR, Trutakna also demonstrated a remarkable impact on kidney disease progression. Crucially, no patients in the Trutakna treatment group required dialysis for more than 30 days or a kidney transplant, a significant achievement when compared to the eight patients in the placebo cohort who faced these life-altering interventions. The composite endpoint for kidney disease progression also showed a marked reduction, with only 11 events observed in the Trutakna group compared to 38 in the placebo arm, highlighting the drug’s ability to significantly alter the natural course of the disease.
Furthermore, Trutakna successfully met its hierarchically tested endpoints, achieving statistically significant reductions in proteinuria, galactose-deficient IgA1 (Gd-IgA1) – a hallmark biomarker of IgAN – and haematuria. These comprehensive results not only support the initial accelerated approval but strongly advocate for its full approval.
A Chronology of Trutakna’s Journey to Full Approval
Trutakna’s path to potential full approval has been marked by strategic development and a phased approach to regulatory engagement. The journey began with the pivotal Phase III ORIGIN 3 trial, designed to evaluate the drug’s efficacy and safety in adults with primary IgAN at risk for disease progression.
July 2026: Accelerated Approval Granted
The US Food and Drug Administration (FDA) initially granted Trutakna accelerated approval in July 2026. This critical decision was based on an interim analysis of the ORIGIN 3 trial. At the 36-week mark, patients receiving Trutakna demonstrated a significant 46% reduction from baseline in proteinuria. More importantly, the drug achieved a statistically significant and clinically meaningful 42% reduction in proteinuria compared to placebo, indicating a rapid and impactful response in a key disease marker. This early success paved the way for broader patient access and further evaluation.
Present Day: Confirmatory Data Solidifies Case for Full Approval
The release of the latest 52-week and 104-week data from the ORIGIN 3 trial represents the crucial confirmatory evidence required for full regulatory approval. These extended results showcase not only the sustained reduction in proteinuria but also significant improvements in kidney function (eGFR) and a marked decrease in kidney disease progression events. This robust dataset provides a comprehensive picture of Trutakna’s long-term benefits.
Q4 2026: Supplemental BLA Submission Planned
Buoyed by the overwhelmingly positive confirmatory data, Vera Therapeutics has announced its intention to submit a supplemental Biologics License Application (BLA) to the FDA in the fourth quarter of 2026. This submission will formally present the complete clinical data package for Trutakna, seeking to transition the drug from accelerated to full approval.
2027: Anticipated Full Approval
With the planned BLA submission and the strength of the supporting data, Vera Therapeutics anticipates potential full approval of Trutakna in 2027. This would represent a significant milestone for the company and, more importantly, for the IgAN patient community, offering a more definitive and long-term treatment option.
Unpacking the Supporting Data: A Deep Dive into Trutakna’s Efficacy
The clinical efficacy of Trutakna is underscored by a wealth of quantitative data from the ORIGIN 3 trial, painting a clear picture of its impact on multiple facets of IgAN pathology.
eGFR Stabilization: A Lifeline for Kidney Function
The primary measure of Trutakna’s success in preserving kidney function lies in its effect on eGFR.
- 52-Week Data: At the 52-week mark, the mean eGFR change from baseline in the Trutakna group was a mere -0.1 mL/min/1.73m². In stark contrast, the placebo group experienced a significant decline of -5.7 mL/min/1.73m². This difference of 5.6 mL/min/1.73m² is highly statistically significant and clinically meaningful, indicating Trutakna’s ability to effectively halt or drastically slow kidney function decline.
- 104-Week Data: The positive trend was sustained and even amplified over the longer term. The annualised eGFR slope through 104 weeks showed a minimal drop of -0.6 in the treatment arm, compared to a substantial -5.6 in the placebo cohort. This demonstrates Trutakna’s capacity for sustained renoprotection over a two-year period, a critical factor for managing a chronic disease like IgAN.
Reducing Kidney Disease Progression: Averted Disasters
The impact of Trutakna on preventing severe kidney disease progression events is a major differentiator.
- Dialysis and Transplant: In a critical finding, zero patients in the Trutakna treatment group required dialysis for more than 30 days or a kidney transplant. This is a profound outcome, as these interventions represent significant burdens on patients’ lives and healthcare systems. Conversely, eight patients in the placebo cohort reached this stage of disease progression.
- Composite Kidney Disease Progression: The composite endpoint, which includes various measures of disease worsening, also showed a significant benefit. There were only 11 events in the Trutakna group compared to 38 events in the placebo group, representing a substantial reduction in the overall risk of kidney disease progression.
Key Biomarker Reductions: Targeting the Disease at its Root
Trutakna’s mechanism of action, which targets the underlying immune dysregulation in IgAN, is reflected in its ability to reduce key biomarkers.
- Proteinuria: As the basis for its accelerated approval, Trutakna achieved a statistically significant and clinically meaningful 42% reduction in proteinuria compared to placebo at 36 weeks. This reduction is crucial as proteinuria is a strong predictor of IgAN progression.
- Galactose-Deficient IgA1 (Gd-IgA1): Trutakna demonstrated statistically significant reductions in Gd-IgA1 levels, a key pathogenic autoantigen in IgAN. This indicates that the drug is effectively modulating the immune response that drives the disease.
- Haematuria: The drug also achieved statistically significant reductions in haematuria, another indicator of kidney inflammation and damage.
Official Responses: Optimism and Strategic Vision
The release of these compelling data has been met with enthusiastic responses from Vera Therapeutics leadership, underscoring their confidence in Trutakna’s future.
Dr. Marshall Fordyce, Founder and CEO of Vera Therapeutics, expressed his optimism regarding the confirmatory data: "We believe that upstream inhibition of BAFF and APRIL with Trutakna achieves results that reflect the potential for comprehensive disease modification in IgAN. The final results support this alignment, and we plan to submit the supplemental BLA in the fourth quarter of this year. We look forward to the potential full approval of Trutakna in 2027."
Dr. Fordyce’s statement highlights the strategic intent behind Trutakna’s development – to not just manage symptoms but to fundamentally alter the disease’s progression. The upstream inhibition of B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) by Trutakna targets the core immune dysregulation implicated in IgAN, offering a novel therapeutic approach.
The strong physician and patient interest in Trutakna is already evident. In the mere 10 weeks since its accelerated approval, Vera Therapeutics has received over 350 patient start forms. This high volume of interest suggests a significant unmet need and a rapid adoption of Trutakna by clinicians eager to offer a new treatment option to their patients.
Implications for the IgAN Landscape and Beyond
The robust data supporting Trutakna’s full approval arrives at a pivotal moment for the IgAN market, which is experiencing significant growth and innovation. Vera Therapeutics’ success is not occurring in a vacuum; it is part of a wave of promising new therapies emerging for this previously underserved condition.
A Burgeoning Market for IgAN Therapies:
The growing pipeline of IgAN treatments signifies a paradigm shift in how the disease is managed. Several other companies are making significant strides:
- Otsuka’s Voyxact (sibeprenlimab-szsi): In August, Otsuka announced positive two-year data from its Phase III VISIONARY trial. Voyxact demonstrated an annualised eGFR slope stabilization of -0.3 mL/min/1.73m²/year, compared to a decline of -4.2 mL/min/1.73m²/year with placebo. This drug, also targeting Gd-IgA1, shows similar promise in stabilizing kidney function.
- Novartis’s Vanrafia (atrasentan): In February 2026, Novartis presented final data from its Phase III ALIGN trial. Vanrafia, an endothelin receptor antagonist, showed a 2.39 mL/min/1.73m² difference in eGFR change from baseline compared to placebo at week 136, even after treatment discontinuation, indicating a lasting benefit. Novartis has indicated its intention to seek full FDA approval.
- Vertex Pharmaceuticals’ Povetacicept: In March 2026, Vertex announced its intent to seek approval for povetacicept, an engineered fusion protein that inhibits both BAFF and APRIL. This dual inhibitor met its primary endpoint in the Phase III RAINER trial, positioning it as another potential significant player in the IgAN space.
- Established Therapies: More established therapies like Calliditas Therapeutics’ Tarpeyo (budesonide) and Travere Therapeutics’ Filspari (sparsentan) have already navigated the regulatory pathway, securing accelerated approvals in 2021 and 2023 respectively, and subsequently achieving full approvals in late 2023 and 2024. These successes have paved the way for new entrants and validated the therapeutic potential in IgAN.
Trutakna’s Unique Position and Mechanism:
Trutakna’s mechanism of action as a TACI receptor inhibitor that binds to BAFF and APRIL is a sophisticated approach to modulating B-cell activity, which is central to IgAN pathogenesis. The comprehensive data demonstrating its efficacy across multiple endpoints – eGFR, disease progression, proteinuria, Gd-IgA1, and haematuria – positions Trutakna as a potentially highly effective and multi-faceted treatment. The company’s confidence in achieving full approval in 2027, coupled with strong early uptake, suggests Trutakna is poised to capture a significant share of this expanding market.
The news surrounding Trutakna’s confirmatory data is a beacon of hope for patients suffering from IgA nephropathy. With its demonstrated ability to significantly slow disease progression and preserve kidney function, Trutakna is on a clear path towards full FDA approval, promising to reshape the treatment landscape for this chronic and challenging kidney disease.
About the Author
